Pacira BioSciences (PCRX) Gross Profit (2010 - 2026)

Pacira BioSciences' Gross Profit history runs 17 years deep, the most recent figure standing at $141.0 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 4.71% year-over-year to $141.0 million in Q1 2026; TTM through Mar 2026 was $583.0 million, a 6.88% increase from a year earlier, with the FY2025 full-year figure at $576.7 million, up 8.69% from the prior year.
• Gross Profit retreated to $141.0 million in Q1 2026 per PCRX's latest filing, from $156.6 million in the prior quarter.
• Across five years, Gross Profit topped out at $156.6 million in Q4 2025 and bottomed at -$554.1 million in Q4 2022.
• The 5-year median for Gross Profit is $129.7 million (2024), against an average of $90.7 million.
• Across the five-year window, Gross Profit tumbled 561.04% in 2022 and surged 124.1% in 2023, its largest moves.
• Year by year, Gross Profit stood at -$554.1 million in 2022, then surged by 124.1% to $133.6 million in 2023, then advanced by 10.34% to $147.4 million in 2024, then climbed by 6.25% to $156.6 million in 2025, then fell by 9.97% to $141.0 million in 2026.
• Per Business Quant, the three latest PCRX Gross Profit figures stand at $141.0 million (Q1 2026), $156.6 million (Q4 2025), and $145.2 million (Q3 2025).